InflaRx N.V. IFRX
1.18 USD -0.03 (-2.48%)
At closeNov 12, 2026, 4:14 AM EST
1.08 -0.10 -8.47%
Pre-market · Nov 12, 4:14 AM ET
1.17 Day range 1.30
0.798 52-week range 2.95
- YTD
- +16.83%
- 1 year
- -28.48%
News
defenseworld.net Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX) Travere Therapeutics (NASDAQ: TVTX - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
benzinga.com InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses…
globenewswire.com InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
benzinga.com InflaRx Q3 EPS $(0.02) Beats $(0.07) Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 90.48 percent increase over losses of $(0.21) per…